Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

Prior treatment

• Participation in another clinical study with a research product during the last 30 days before inclusion.

Other

• Indication other than clear cell renal cell carcinoma for these same ITKs
• Pregnant or breast-feeding subjects
• Patient whose regular follow-up is impossible for psychological, family, social or geographic reasons,
• Patient under guardianship, curatorship or safeguard of justice

• Patient followed for metastatic clear cell renal cell carcinoma.
• Age ≥18 years old.
• Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1 or 2
• Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib for metastatic kidney cancer.
• If patient doesn't have renal failure -\> group 1, or if patient has chronic renal failure according to the moderate stage Chronic Kidney Disease - Epidemiology (CKD-EPI) formula (Clr \<60 ml / min, stage 3) -\> group 2, or if patient have chronic renal failure according to the CKD-EPI formula of severe or terminal stage (Clr \<30 ml / min, stage 4 and stage 5), with or without dialysis -\> group 3.
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
• Patient having given informed, written and express consent.
• Affiliation to the French Social Security System.